Incyte Corp. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Incyte Corp. (INCY) shares rose 1.50% to $117.39, outperforming competitors like Alnylam and Bio-Techne during a strong market session where the S&P 500 and Dow Jones also gained. Trading volume exceeded its 50-day average, and the stock closed just below its 52-week high of $119.60.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) advanced 1.50% to $117.39 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.89% to 7,509.20 and the Dow Jones Industrial Average rising 0.74% to 52,224.64.
Incyte Corp. closed 1.85% short of its 52-week high of $119.60, which the company reached on July 17th.
The stock outperformed some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. (ALNY) fell 0.48% to $271.37, Bio-Techne Corp. (TECH) fell 0.01% to $71.63, and BioMarin Pharmaceutical Inc. (BMRN) rose 0.17% to $59.21.
Trading volume (1.9 M) eclipsed its 50-day average volume of 1.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-21-26 1703ET